Eli Lilly and Co

🇺🇸United States
Ownership
-
Employees
43K
Market Cap
$859.4B
Website
Introduction

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes

First Posted Date
2020-11-23
Last Posted Date
2022-01-11
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
67
Registration Number
NCT04641312
Locations
🇩🇪

Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany

🇩🇪

Profil Mainz, Mainz, Germany

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

First Posted Date
2020-11-18
Last Posted Date
2022-07-01
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1755
Registration Number
NCT04634409
Locations
🇺🇸

VITALINK - Anderson, Anderson, South Carolina, United States

🇺🇸

Smart Cures Clin Research, Anaheim, California, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 135 locations

A Study of LY3462817 in Participants With Rheumatoid Arthritis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-11-18
Last Posted Date
2023-07-12
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
98
Registration Number
NCT04634253
Locations
🇺🇸

Physician Research Collaboration, LLC, Lincoln, Nebraska, United States

🇨🇿

PV Medical Services s.r.o., Zlin, Czechia

🇲🇽

Centro Medico del Angel, Mexicali, Baja California, Mexico

and more 22 locations

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-11-13
Last Posted Date
2023-11-02
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
202
Registration Number
NCT04627038
Locations
🇺🇸

Rainier Clinical Research Center, Renton, Washington, United States

🇺🇸

University of Miami Don Suffer Clinical Research Building, Miami, Florida, United States

🇺🇸

New Horizon Research Center, Miami, Florida, United States

and more 36 locations

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2020-11-12
Last Posted Date
2023-10-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
254
Registration Number
NCT04626297
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

Modern Research Associates, Dallas, Texas, United States

🇺🇸

Premier Clinical Research, Spokane, Washington, United States

and more 81 locations

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2020-11-04
Last Posted Date
2024-12-27
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
300
Registration Number
NCT04616326
Locations
🇮🇹

Neuroscience, Roma, Italy

🇺🇸

Medical Research Partners - Logan, Logan, Utah, United States

🇺🇸

Rehabilitation & Neurological Services, Huntsville, Alabama, United States

and more 85 locations

A Study of LY3832479 (LY-CoV016) in Healthy Participants 1

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-11-02
Last Posted Date
2021-12-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
18
Registration Number
NCT04611789
Locations
🇺🇸

Covance Clinical Research Inc, Daytona Beach, Florida, United States

A Study of Mirikizumab in Healthy Participants

First Posted Date
2020-10-29
Last Posted Date
2024-02-20
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
240
Registration Number
NCT04607733
Locations
🇺🇸

QPS, Springfield, Missouri, United States

🇺🇸

Covance Dallas, Dallas, Texas, United States

🇺🇸

Covance Clinical Research Inc, Madison, Wisconsin, United States

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2020-10-28
Last Posted Date
2023-03-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
187
Registration Number
NCT04605991
Locations
🇺🇸

Endocrine and Metabolic Consultants, Rockville, Maryland, United States

🇺🇸

Encore Medical Research, Hollywood, Florida, United States

🇺🇸

Metabolic Research Institute, Inc., West Palm Beach, Florida, United States

and more 28 locations

Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19

Conditions
First Posted Date
2020-10-27
Last Posted Date
2023-10-02
Lead Sponsor
Eli Lilly and Company
Registration Number
NCT04603651
© Copyright 2024. All Rights Reserved by MedPath